Table 1.
Baseline demographics and clinical characteristics
| Characteristic | Dacarbazine (n=338) | Vemurafenib (n=337) |
|---|---|---|
| Median age (range), years | 52 (17–86) | 56 (21–86) |
| Male | 181 (54) | 200 (59) |
| White race | 338 (100) | 333 (99) |
| Geographic region | ||
| Australia/New Zealand | 38 (11) | 39 (12) |
| North America | 86 (25) | 86 (26) |
| Western Europe | 203 (60) | 205 (61) |
| Other | 11 (3) | 7 (2) |
| ECOG PS | ||
| 0 | 230 (68) | 229 (68) |
| 1 | 108 (32) | 108 (32) |
| LDH level | ||
| Normal (≤ULN) | 142 (42) | 142 (42) |
| Elevated (>ULN) | 196 (58) | 195 (58) |
| Disease stage | ||
| Unresectable IIIC | 13 (4) | 20 (6) |
| M1a | 40 (12) | 34 (10) |
| M1b | 65 (19) | 62 (18) |
| M1c | 220 (65) | 221 (66) |
Reproduced with permission from Chapman PB et al. N Engl J Med 2011; 364: 2507–2516, Copyright Massachusetts Medical Society.
Unless otherwise indicated, all data are n (%).
ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; ULN, upper limit of normal.